NEWS
Discover how Chroma is expanding our impact.
PRESS RELEASES
Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing
Cambridge, MA, November 17, 2021 – Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, launched today with $125M in financing. Atlas Venture and Newpath Partners seeded the company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T. Rowe Price Associates, Inc., and Wellington Management in addition to all seed investors.The financing will support continued development of the company’s epigenetic editing platform and advancement of its pipeline of targeted therapeutics. Chroma has assembled a highly experienced…
IN THE NEWS
Aiming for on/off switch of genes, Chroma corrals $125M for new wave of medicines
IN THE NEWS
Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders